The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) who received first- or second-line immunotherapies (IO) in the United States (US).
 
Marley Boyd
Employment - McKesson
 
Srinivas Annavarapu
Employment - McKesson
Research Funding - Merck Sharp & Dohme (Inst)
 
Gurjyot K. Doshi
Speakers' Bureau - Astellas Medivation
 
Kentaro Imai
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Eric Sbar
Employment - Merck Sharp & Dohme; Pfizer
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
Research Funding - Merck Sharp & Dohme; Pfizer
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Pfizer
 
James Luke Godwin
Employment - Merck
 
Haojie Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group